Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00797719 | Short Neoadjuvant Hemithoracic IMRT for MPM | completed | Phase 1 / Phase 2 | 104 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04166734 | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma(MESO-PRIME) | terminated | Phase 1 | 5 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 4, 2026 |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 219 | TYK Medicines, IncINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT03760575 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | recruiting | Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT05932199 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | recruiting | Phase 1 / Phase 2 | 52 | Baylor College of MedicineOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05449366 | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma(INTERACT MESO) | completed | Phase 1 / Phase 2 | 7 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | not yet recruiting | Phase 1 / Phase 2 | 55 | National Cancer Center, ChinaOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04153565 | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT04525859 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | completed | Phase 1 | 19 | Oncovir, Inc.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT00629343 | Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | completed | Phase 1 | 27 | Columbia UniversityOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06726564 | A Study of MT027 in Patients with Pleural Malignant Tumors | recruiting | Phase 1 | 18 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT03546426 | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies(MESOVAX) | active not recruiting | Phase 1 | 18 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06452160 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 103 | BridGene Biosciences Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02707666 | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | terminated | Phase 1 | 7 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06256055 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors | unknown | Phase 1 | 24 | UTC Therapeutics Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03319537 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | terminated | Phase 1 / Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2026source: clinicaltrials